Original Article

Pharmacoeconomic analysis of Oral and Injectable Proton Pump Inhibitors available in India

Abstract

Introduction: Proton pump inhibitors (PPIs) effectively suppress acid secretion and play an essential role in peptic ulcer disease and gastroesophageal reflux disease. There is a genuine concern about overutilizing PPIs, leading to significantly high costs and undesirable outcomes. An increase in the patient medication cost was associated with decreased adherence to prescription medication. Hence, this study assessed the cost variation of proton pump inhibitors (PPI) drugs. Methods: The cost of different brands of commonly used PPIs was sorted out by referring latest “Monthly Index of Medical Specialties” October – December 2021, and 1mg online pharmacy. The cost of 10 dosage forms (Tablets/capsules) in INR of each brand, Cost Ratio, and Percentage Cost Variation for individual drug brands was calculated in the case of an oral drug, and the cost of one vial or ampoule was noted in the case of injectable drug. At last, the cost ratio and percentage cost variation of various brands was compared. Results: The data analysis showed a significant variation in the costs of different brands of proton pump inhibitors available In the Indian market. Percentage variation in cost for oral preparations of proton pump inhibitors marketed in India was found to be tablet/capsule Rabeprazole 20mg (1540%), Omeprazole 20 mg(718.18%), Pantoprazole  40mg (504.16%), Esomeprazole 20mg (173.68%), Lansoprazole 15 mg (84.90 %), Omeprazole  40 mg (60.34%) and with injectable preparations IVR abeprazole 20mg (1090.90%), Omeprazole  40 mg  (347.36%), Esomeprazole 40mg (216.66%), Pantoprazole 20mg (164.44 %), Pantoprazole 40mg (51.16%). Conclusion: There is a wide variation in the prices of proton pump inhibitors available in the market. Regulatory authorities, pharma companies, and physicians should maximize their efforts to reduce the cost of drugsThe need to search for reliable process indicators for the effectiveness of anti-diabetic therapy has been expressed in the literature. Process indicators have been described as essential processes that contribute to achieving outcomes

Atkins AM, Chandra Sekar RM. Proton pump inhibitors: their misuse, overuse, and abuse. IOSR J Pharm. 2013; 3(2): 25-9. DOI: 10.9790/3013-32202529

Sachs G, Shin, Moo J, Olga V, Lambrecht N, Iskandar Y, Munson K. The Gastric H, K ATPase as a Drug Target. J CliGastroenterol. 2007; 41(2):226-42. PMCID: PMC2860960 DOI: 10.1097/MCG.0b013e31803233b7

Moore M, Gould P, Keary BS. Global urbanization and impact on health. Int J Hyg Environ Health. 2003; 206:269-78. [PubMed: 12971682] doi: 10.1078/1438-4639-00223.

Ibrahim H, Awadalla. Health effect of slums: A consequence of urbanization. Serbian Journal of Management. 2013; 3:7-14.

Mohammed KM, Suman C, Bogadi V, Prabhakar B, Rao KPR, Devi S, et al. Epidemic trends of upper gastrointestinal tract abnormalities: hospital-based study on endoscopic data evaluation. Asian Pac J Cancer Prev. 2015; 16(14):5741-7. PMID: 26320445

DOI: 10.7314/apjcp.2015.16.14.5741

Forte JG, Lee HC. "Gastric adenosine triphosphatases: A review of their possible role in HCl secretion." Gastroenterol. 1977; 73(4 Pt 2): 921- 6

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci., 2007; 69(1): 160-3.

Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010; 123(4):358-66. Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004; 17:80– 3. [PubMed]

Bhushan R, Kishore A, Chandra A, Kumar A, Singh HK. Study of the price variation analysis of proton pump inhibitors [PPI] available in Indian pharmaceutical market. Int J Res Med Sci 2021; 9:226-9

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med, 2006; 28(3): 35-8

Bargade MB, Mahatme MS, Hiware S, Admane PD. Cost-minimization analysis of proton pump inhibitors in India. Int J Basic ClinPharmacol 2016; 5:1043-7

Bate, C M et al. "Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group." Gut vol. 36, 4 (1995): 492-8. doi:10.1136/gut.36.4.492

Files
IssueVol 9 No 2 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jppm.v9i2.13369
Keywords
PPI Cost ratio Percentage cost variation

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Deolekar P, Dongerkery K, Yadav P, Sonawane J. Pharmacoeconomic analysis of Oral and Injectable Proton Pump Inhibitors available in India. JPPM. 2023;9(2):1-7.